Raed Samara

Raed Samara

Raed Samara, PhD is a Global Product Manager for NGS technologies at QIAGEN, with a focus on pre-analytics and targeted enrichment. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.


Crossing organ boundaries with NGS to enable precision medicine

The concept of precision medicine represents a paradigm shift in our understanding of diseases and our approach to disease management. The core pillar of the precision medicine concept is the ability “to take into account individual variability in genes” (1) to tailor therapies based on certain genetic changes, such as germline and somatic mutations, that are… Read article →


Infographic on NGS clinical research milestones

DNA mutations have been implicated in several diseases, particularly cancer, and NGS presents an ideal technology to efficiently profile the multitude of mutations in a high-throughput manner. In 2001 the first draft of human genome was published. Since then many major milestones have been achieved. Do you know when PIK3CA mutations were identified in colon cancer?… Read article →